Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Palivizumab Prophylaxis for Healthy Preterm Infants: More Data Supporting American Academy of Pediatrics Guidelines.

× No keyword cloud information.

11 in total

1. Observed Effectiveness of Palivizumab for 29-36-Week Gestation Infants.

Authors: Harold J Farber; Frederick J Buckwold; Barry Lachman; J Scott Simpson; Ernest Buck; Matha Arun; Adolfo M Valadez; Teresa Ruiz; Joy Alonzo; Andrea Henry; Nneka Cos-Okpalla; Kelsey Nguyen; William Brendel; James Small; William Brendle Glomb
Journal: Pediatrics Date: 2016-07-18 Impact factor: 7.124

2. RSV immunoprophylaxis: does the benefit justify the cost?

Authors: H Cody Meissner; David W Kimberlin
Journal: Pediatrics Date: 2013-10-14 Impact factor: 7.124

3. Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study.

Authors: Almut G Winterstein; Caitlin A Knox; Paul Kubilis; Christian Hampp
Journal: JAMA Pediatr Date: 2013-12 Impact factor: 16.193

4. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors:
Journal: Pediatrics Date: 1998-09 Impact factor: 7.124

5. Respiratory syncytial virus-associated mortality in hospitalized infants and young children.

Authors: Carrie L Byington; Jacob Wilkes; Kent Korgenski; Xiaoming Sheng
Journal: Pediatrics Date: 2014-12-08 Impact factor: 7.124

6. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.

Authors:
Journal: Pediatrics Date: 1998-11 Impact factor: 7.124

7. Trends in bronchiolitis hospitalizations in the United States, 2000-2009.

Authors: Kohei Hasegawa; Yusuke Tsugawa; David F M Brown; Jonathan M Mansbach; Carlos A Camargo
Journal: Pediatrics Date: 2013-06-03 Impact factor: 7.124

8. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.

Authors:
Journal: Pediatrics Date: 2014-08 Impact factor: 7.124

Palivizumab Prophylaxis for Healthy Preterm Infants: More Data Supporting American Academy of Pediatrics Guidelines.